Complete hepatitis B virus genome analysis in chronically infected children before and during lamivudine treatment

Journal of Medical Virology

Volumn 77, Issue 2, 2005, Pages 194-202

  Conzelmann, Isabel ^a,b   Wintermeyer, Philip ^a   Wirth, Stefan ^a   Radke, Robert ^a   Gerner, Patrick ^a,c  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c HELIOS KLINIKUM WUPPERTAL   (Germany)

Author keywords

Childhood; Full length genome; Resistance

Indexed keywords

LAMIVUDINE;

ARTICLE; CHILDHOOD DISEASE; CHRONIC DISEASE; CONTROLLED STUDY; EARLY DIAGNOSIS; GENE AMPLIFICATION; GENE MUTATION; GENETIC ANALYSIS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; LONGITUDINAL STUDY; MUTATION RATE; NONSENSE MUTATION; SUBSTITUTION REACTION; VIRUS GENE;

AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; CARRIER STATE; CHILD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENES, VIRAL; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MUTATION, MISSENSE;

HEPATITIS B VIRUS;

EID: 24644441150     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.20436     Document Type: Article

References (39)

1. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, Brown N, Condreay LD. 1998. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 27:1670-1677.
2. Asahina Y, Enomoto N, Ogura Y, Kurosaki M, Sakuma I, Izumi N, Marumo F, Sato C. 1996. Sequential changes in full-length genomes of hepatitis B virus accompanying acute exacerbation of chronic hepatitis B. J Hepatol 25:787-794.
3. Boni C, Bertoletti A, Penna A, Cavalli A, Pilli M, Urbani S, Scognamiglio P, Boehme R, Panebianco R, Fiaccadori F, Ferrari C. 1998. Lamivudine treatment can restore T-cell responsiveness in chronic hepatitis B. J Clin Invest 102:968-975.
4. Boni C, Penna A, Bertoletti A, Lamonaca V, Rapti I, Missale G, Pilli M, Urbani S, Cavalli A, Cerioni S, Panebianco R, Jenkins J, Ferrari C. 2003. Transient restoration of anti-viral T-cell responses induced by lamivudine therapy in chronic hepatitis B. J Hepatol 39:595-605.
5. Boucher CA, Cammack N, Schipper P, Schuurman R, Rouse P, Wainberg MA, Cameron JM. 1993. High-level resistance to (-) enantiomeric 2′-deoxy- 3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 37:2231-2234.
6. Bozkaya H, Ayola B, Lok AS. 1996. High rate of mutations in the hepatitis B core gene during the immune clearance phase of chronic hepatitis B virus infection. Hepatology 24:32-37.
7. Bozkaya H, Akarca US, Ayola B, Lok AS. 1997. High degree of conservation in the hepatitis B virus core gene during the immune tolerant phase in perinatally acquired chronic hepatitis B virus infection. J Hepatol 26:508-516.
8. Chayama K, Suzuki Y, Kobayashi M, Kobayashi M, Tsubota A, Hashimoto M, Miyano Y, Koike H, Kobayashi M, Koida I, Arase Y, Saitoh S, Murashima N, Ikeda K, Kumada H. 1998. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 27:1711-1716.
9. Chen HB, Fang DX, Li FQ, Jing HY, Tan WG, Li SQ. 2003. A novel hepatitis B virus mutant with A-to-G at nt551 in the surface antigen gene. World J Gastroenterol 9:304-308.
10. Dusheiko G. 1998. Lamivudine treatment of chronic hepatitis B. Rev Med Virol 8:153-159.
11. Fu L, Cheng YC. 1998. Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance. Biochem Pharmacol 55:1567-1572.
12. Galibert F, Mandart E, Fitoussi F, Tiollais P, Charnay P. 1979. Nucleotide sequence of the hepatitis B virus genome (subtype ayw) cloned in E. coli. Nature 281:646-650.
13. Gao Q, Gu Z, Parniak MA, Cameron J, Cammack N, Boucher C, Wainberg MA. 1993. The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2′,3′-dideoxyinosine and 2′,3′- dideoxycytidine confers high-level resistance to the (-) enantiomer of 2′,3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother 37:1390-1392.
14. Gunther S, Paulij W, Meisel H, Will H. 1998. Analysis of hepatitis B virus populations in an interferon-alpha-treated patient reveals predominant mutations in the C-gene and changing e-antigenicity. Virology 244:146-160.
15. Hannoun C, Horal P, Lindh M. 2000. Long-term mutation rates in the hepatitis B virus genome. J Gen Virol 81:75-83.
16. Honkoop P, Niesters HG, de Man RA, Osterhaus AD, Schalm SW. 1997. Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. J Hepatol 26:1393-1395.
17. Jonas MM, Kelley DA, Mizerski J, Badia IB, Areias JA, Schwarz KB, Little NR, Greensmith MJ, Gardner SD, Bell MS, Sokal EM. 2002. Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med 346:1706-1713.
18. Kim KH, Lee KH, Chang HY, Ahn SH, Tong S, Yoon YJ, Seong BL, Kim SI, Han KH. 2003. Evolution of hepatitis B virus sequence from a liver transplant recipient with rapid breakthrough despite hepatitis B immune globulin prophylaxis and lamivudine therapy. J Med Virol 71:367-375.
19. Kobayashi S, Ide T, Sata M. 2001. Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers. J Hepatol 34:584-586.
20. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL, Gray DF. 1998. A 1-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 339:61-68.
21. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, Lim SG, Wu PC, Dent JC, Edmundson S, Condreay LD, Chien RN. 2001. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy. Hepatology 33:1527-1532.
22. Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Chien RN, Dent J, Roman L, Edmundson S, Lai CL. 2000. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 119:172-180.
23. Liu CJ, Chen PJ, Lai MY, Kao JH, Chen DS. 2001. Hepatitis B virus variants in patients receiving lamivudine treatment with breakthrough hepatitis evaluated by serial viral loads and full-length viral sequences. Hepatology 34:583-589.
24. Locarnini S. 2003. Hepatitis B viral resistance: Mechanisms and diagnosis. J Hepatol 39:S124-S132.
25. Lok AS, Hussain M, Cursano C, Margotti M, Gramenzi A, Grazi GL, Jovine E, Benardi M, Andreone P. 2000. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. Hepatology 32:1145-1153.
26. Niesters HG, Honkoop P, Haagsma EB, de Man RA, Schalm SW, Osterhaus AD. 1998. Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment. J Infect Dis 177:1382-1385.
27. Ogata N, Fujii K, Takigawa S, Nomoto M, Ichida T, Asakura H. 1999. Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in Japanese patients with chronic hepatitis B. J Med Virol 59:270-276.
28. Okamoto H, Imai M, Kametani M, Nakamura T, Mayumi M. 1987. Genomic heterogeneity of hepatitis B virus in a 54-year-old woman who contracted the infection through materno-fetal transmission. Jpn J Exp Med 57:231-236.
29. Orito E, Mizokami M, Ina Y, Moriyama EN, Kameshima N, Yamamoto M, Gojobori T. 1989. Host-independent evolution and a genetic classification of the hepadnavirus family based on nucleotide sequences. Proc Natl Acad Sci USA 86:7059-7062.
30. Roznovsky L, Harrison TJ, Fang ZL, Ling R, Lochman I, Orsagova I, Pliskova L. 2000. Unusual hepatitis B surface antigen variation in a child immunised against hepatitis B. J Med Virol 61:11-14.
31. Schuurman R, Nijhuis M, van Leeuwen R, Schipper P, de Jong D, Collis P, Danner SA, Mulder J, Loveday C, Christopherson C. 1995. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis 171:1411-1419.
32. Seddigh-Tonekaboni S, Waters JA, Jeffers S, Gehrke R, Ofenloch B, Horsch A, Hess G, Thomas HC, Karayiannis P. 2000. Effect of variation in the common "a" determinant on the antigenicity of hepatitis B surface antigen. J Med Virol 60:113-121.
33. Thibault V, Aubron-Olivier C, Agut H, Katlama C. 2002. Primary infection with a lamivudine-resistant hepatitis B virus. AIDS 16:131-133.
34. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL. 1996. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 24:714-717.
35. Torresi J. 2002. The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus. J Clin Virol 25:97-106.
36. Torresi J, Earnest-Silveira L, Deliyannis G, Edgtton K, Zhuang H, Locarnini SA, Fyfe J, Sozzi T, Jackson DC. 2002. Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology 293:305-313.
37. Uchida T, Aye TT, Shikata T, Yano M, Yatsuhashi H, Koga M, Mima S. 1994. Evolution of the hepatitis B virus gene during chronic infection in seven patients. J Med Virol 43:148-154.
38. Yeh CT, Chien RN, Chu CM, Liaw YF. 2000. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology 31:1318-1326.
39. Zollner B, Stoehr A, Plettenberg A, Feucht H, Schroter M, Schafer P, Laufs R. 2000. In vivo dynamics and pathogenicity of wild-type and resistant Hepatitis B virus during long-term lamivudine monotherapy-a clinical note. J Clin Virol 17:183-188.